ZVRA — ZEVRA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434647 ·
Last close
$9.40
Market Cap
$559.34M
52W High
$15.03
52W Low
$8.01
ADV30
977,693
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 37,756,000 | 35,962,000 | 11,580,000 | 19,208,000 | 313,575,000 | 122,148,000 | 74,652,000 |
| Jun 2026 | 39,663,000 | 38,138,000 | 16,777,000 | 8,752,000 | 302,712,000 | 145,321,000 | 85,060,000 |
| Mar 2026 | 36,220,000 | 34,323,000 | 8,832,000 | 37,890,000 | 278,579,000 | 95,595,000 | 72,775,000 |
| Dec 2025 | 34,125,000 | 32,605,000 | 9,315,000 | 12,165,000 | 284,731,000 | 62,406,000 | 130,074,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$38,737,000
Investing CF
$76,445,000
Financing CF
$-47,122,000
CapEx
$-1,044,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.99
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-356,210,000
Inventory
$3,070,000
Receivables
$19,943,000
ST Investments
$73,420,000
EBIT TTM
$93,641,000
Pretax Income TTM
$89,982,000
Interest Exp TTM
$3,659,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$147,764,000
EBITDA
$47,976,000
Free Cash Flow
$51,229,124
Enterprise Value
$495,318,560
Total Cash
$195,568,000
Total Debt
$1,228,000
Shares Out
59,504,621
Trailing EPS
$1.22
Book Value
$4.02
ROE
41.9%
ROA
10.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 106,470,000 | -4,233,000 | 83,229,000 | 284,731,000 | 130,074,000 | 154,657,000 | -1,598,000 |
| Dec 2024 | 23,612,000 | -87,003,000 | -105,511,000 | 178,127,000 | 138,461,000 | 39,666,000 | -69,665,000 |
| Dec 2023 | 27,461,000 | -49,604,000 | -46,049,000 | 172,327,000 | 110,463,000 | 61,864,000 | -33,535,000 |
| Dec 2022 | 10,161,000 | -24,902,000 | -26,772,000 | 115,340,000 | 40,220,000 | 75,120,000 | -18,717,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$136,071,000
NetIncome TTM
$58,263,000
OpCashFlow TTM
—
Assets (Latest)
$302,712,000
Forward EPS
$1.05
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.00 · spot: $9.28 · call volume: 618 · put volume: 2,046
Expected Move to 2027-02-19:
±$2.88
(31.03%) —
implied range
$6.40 –
$12.16
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WVE | Wave Life Sciences, Inc. | $560.13M | $2.84 | — |
| ANL | Adlai Nortye Group Ltd. | $556.80M | $9.48 | — |
| AVBP | ArriVent BioPharma, Inc. | $552.92M | $10.69 | — |
| CLYM | Climb Bio, Inc. | $574.46M | $9.78 | — |
| ACRS | Aclaris Therapeutics, Inc. | $536.11M | $3.38 | — |
News headlines (Yahoo Finance, 1h cache)
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
2026-11-18 12:30 · Yahoo
Zevra’s Lead Drug Faces Potential European Setback – ZVRA Stock Heads For Worst Day In A Month
2026-11-13 13:32 · Yahoo
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
2026-11-13 11:26 · Yahoo
Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade
2026-11-09 13:55 · Yahoo
Zevra (ZVRA) Q3 2026 Earnings Call Transcript
2026-11-04 16:16 · Yahoo
Zevra Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ...
2026-11-04 07:10 · Yahoo
Zevra Therapeutics Q3 Earnings Call Highlights
2026-11-03 23:14 · Yahoo
Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
2026-11-03 21:50 · Yahoo
Zevra Therapeutics: Q3 Earnings Snapshot
2026-11-03 21:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.